Drug Profile
Research programme: antibody therapeutics - Adimab/Potenza Therapeutics
Latest Information Update: 28 Feb 2019
Price :
$50
*
At a glance
- Originator Adimab
- Class Bispecific antibodies; Monoclonal antibodies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Feb 2019 No recent reports of development identified for research development in Unspecified in USA
- 14 Dec 2018 Potenza Therapeutics has been acquired by Astellas Pharma
- 09 Jan 2015 Early research in Undefined indication in USA (unspecified route)